Loading…
Employees: 2,252
Size Anhui Huaheng Biotechnology (688639.SS) is a China Health Care company (Biotechnology) with a market value of $688M, the 3097th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥16.90 on 6 Nov 2026.
Performance Over six months the shares fell 39.6%, against -22.0% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue grew 7.5% over the last twelve months (peer median +7.9%); the operating margin is 3.5% (peer median -105.4%).
Valuation It trades at 25.4× forward earnings against a peer median of 20.7× (2nd most expensive of 4).
Capital Return on invested capital runs 2.4 points below its cost of capital (7.7% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.04B | CN¥2.86B | CN¥2.18B | CN¥1.94B | CN¥1.42B |
| Revenue growth | — | +31% | +12% | +37% | — |
| Gross profit | CN¥766M | CN¥560M | CN¥511M | CN¥756M | CN¥533M |
| EBITDA | n/a | CN¥368M | CN¥330M | CN¥589M | CN¥376M |
| Net income | CN¥96.1M | CN¥132M | CN¥190M | CN¥449M | CN¥320M |
| Free cash flow | -CN¥397M | -CN¥531M | -CN¥724M | -CN¥965M | -CN¥90.3M |
| Capital expenditure | CN¥563M | CN¥637M | CN¥924M | CN¥1.27B | CN¥456M |
| Total debt | CN¥2.47B | CN¥2.10B | CN¥1.58B | CN¥1.30B | CN¥91.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688639.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.9% | -12.5% | 10th highest of 21 |
| 6-month return | -39.6% | -22.0% | 3rd lowest of 19 |
| Distance from 52-week high | -61.2% | -45.3% | 3rd lowest of 21 |
| Revenue growth (TTM) | +7.5% | +7.9% | 7th lowest of 14 |
| Operating margin | 3.5% | -105.4% | 4th highest of 15 |
| Forward P/E | 25.4× | 20.7× | 2nd most expensive of 4 |
| ROIC minus cost of capital | -2.4 pp | -31.6 pp | 3rd highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 25.4× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 20.7× | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 82.0× | 35.4% | +27.2% |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | n/a | -8.3% | -1.3% |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 16.7× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | n/a | 43.2% | +21.5% |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | n/a | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | n/a | -12.3% | -10.9% |